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Proprotein convertase subtilisin kexin type 9
(PCSK9) has been shown to be involved in the
regulation of extracellular levels of the low-
density lipoprotien receptor (LDLR). Although
PCSK9 is a subtilase, it has not been shown to
degrade the LDLR, and its LDLR-lowering
mechanism remains uncertain. Here we report
the crystal structure of human PCSK9 at 2.3 A˚
resolution. PCSK9 has subtilisin-like pro- and
catalytic domains, and the stable interaction
between these domains prevents access to
PCSK9’s catalytic site. The C-terminal domain
of PCSK9 has a novel protein fold and may me-
diate protein-protein interactions. The structure
of PCSK9 provides insight into its biochemical
characteristics and biological function.
INTRODUCTION
Proprotein convertase subtilisin kexin type 9 (PCSK9) is
a serine protease involved in regulating the levels of the
low-density lipoprotein receptor (LDLR) protein (Horton
et al., 2007; Seidah and Prat, 2007). In vitro experiments
have shown that adding PCSK9 to HepG2 cells lowers
the levels of cell surface LDLR (Benjannet et al., 2004;
Lagace et al., 2006; Maxwell et al., 2005; Park et al.,
2004). Experiments with mice have shown that increasing
PCSK9 protein levels decreases levels of LDLR protein in
the liver (Benjannet et al., 2004; Lagace et al., 2006; Max-
well et al., 2005; Park et al., 2004), while PCSK9 knockout
mice have increased levels of LDLR in the liver (Rashid
et al., 2005). Additionally, various human PCSK9 muta-
tions that result in either increased or decreased levels
of plasma LDL have been identified (Berge et al., 2006;
Kotowski et al., 2006; Zhao et al., 2006). PCSK9 has
been shown to directly interact with the LDLR protein, to
be endocytosed along with the LDLR, and to coimmuno-
fluoresce with the LDLR throughout the endosomal path-
way (Lagace et al., 2006). Degradation of the LDLR by
PCSK9 has not been observed, and the mechanismStructure 15, 5through which it lowers extracellular LDLR protein levels
is still uncertain.
PCSK9 is a prohormone-proprotein convertase in the
subtilisin (S8) family of serine proteases (Seidah et al.,
2003). Humans have nine prohormone-proprotein conver-
tases that can be divided between the S8A and S8B
subfamilies (Rawlings et al., 2006). Furin, PC1/PC3, PC2,
PACE4, PC4, PC5/PC6, and PC7/PC8/LPC/SPC7 are
classified in subfamily S8B. Crystal and NMR structures
of different domains frommouse furin and PC1 reveal sub-
tilisin-like pro- and catalytic domains, and a P domain di-
rectly C-terminal to the catalytic domain (Henrich et al.,
2003; Tangrea et al., 2002). Based on the amino acid se-
quence similarity within this subfamily, all seven members
are predicted to have similar structures (Henrich et al.,
2005). SKI-1/S1P and PCSK9 are classified in subfamily
S8A. Sequence comparisons with these proteins also
suggest the presence of subtilisin-like pro- and catalytic
domains (Sakai et al., 1998; Seidah et al., 1999, 2003). In
these proteins the amino acid sequence C-terminal to
the catalytic domain is more variable and does not sug-
gest the presence of a P domain.
Prohormone-proprotein convertases are expressed as
zymogens, and they mature through a multistep process.
The function of the prodomain in this process is two-fold.
The prodomain first acts as a chaperone and is required
for proper folding of the catalytic domain (Ikemura et al.,
1987). Once the catalytic domain is folded, autocatalysis
occurs between the prodomain and catalytic domain. Fol-
lowing this initial cleavage reaction, the prodomain re-
mains bound to the catalytic domain, where it then acts
as an inhibitor of catalytic activity (Fu et al., 2000). When
conditions are correct,maturation proceedswith a second
autocatalytic event at a site within the prodomain (Ander-
son et al., 1997). After this second cleavage event occurs,
the prodomain and catalytic domain dissociate, giving rise
to an active protease.
Autocatalysis of the PCSK9 zymogen occurs between
Gln152 and Ser153 (VFAQjSIP) (Naureckiene et al., 2003)
and has been shown to be required for its secretion from
cells (Seidah et al., 2003). A second autocatalytic event at
a site within PCSK9’s prodomain has not been observed.
Purified PCSK9 is made up of two species that can be
separated by nonreducing SDS-PAGE: the prodomain at45–552, May 2007 ª2007 Elsevier Ltd All rights reserved 545
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The Crystal Structure of PCSK9Table 1. Data Collection and Refinement Statistics
Crystal Name Form 1-Native Form 1-Hg Form 1-Xe Form 2-Native
Data Collection
Wavelength (A˚) 1.0717 1.0063 2.0 1.0
Space group P213 P213 P213 P212121
Cell dimensions
a, b, c (A˚) a = b = c = 139.77 a = b = c = 140.33 a = b = c = 140.15 63.11, 70.71, 150.69
a, b, g () a = b = g = 90 a = b = g = 90 a = b = g = 90 a = b = g = 90
Resolution (A˚) 40–3.1 (3.21–3.1)a 40–3.35 (3.47–3.35) 40–3.15 (3.26–3.15) 40–2.3 (2.38–2.3)
Completeness 99.8 (99.9) 99.9 (100) 99.9 (100) 97.3 (81.7)
Redundancy 5.3 12.1 5.8 4.9
Rsym 6.2 (50.3) 8.4 (46.7) 7.3 (43.7) 12.4 (37.6)
I/sI 20.1 (2.5) 30.9 (5.1) 19.3 (4.0) 10.8 (2.2)
Refinement
Resolution (A˚) 40–2.3
Molecules/ASU 1
Reflections
Total 29,916
Working set 28,405
Test set 1511
Rwork/Rfree 0.196/0.232
Number of atoms
Protein 4,359
Ion 10
Water 215
B factors
Protein 35.83
Ion 95.54
Water 38.06
Rms deviations
Bond lengths (A˚) 0.005
Bond angles () 0.846
aNumbers in parenthesis are for the highest resolution shell.17 kDa and the catalytic plus C-terminal domains at
65 kDa. PCSK9 has not been isolated without its inhibitory
prodomain, and measurements of PCSK9’s catalytic ac-
tivity have been variable (Naureckiene et al., 2003; Seidah
et al., 2003). In order to gain insight into the regulation of
PCSK9’s catalytic activity and how PCSK9 lowers the
level of the LDLR protein, we have determined the crystal
structure of full-length wild-type PCSK9.
RESULTS AND DISCUSSION
Overall Structure of PCSK9
We solved the structure of PCSK9 by multiple isomor-
phous replacement with anomalous scattering and refined546 Structure 15, 545–552, May 2007 ª2007 Elsevier Ltd All righit to 2.3 A˚ resolution (see Experimental Procedures and
Table 1). The crystal structure reveals that PCSK9 has
subtilisin-like pro- and catalytic domains, and a novel C-
terminal domain (termed V domain) (Figure 1). Although
full-length PCSK9 (31–692) was used for crystallization,
electron density is present only for residues 61–683. The
prodomain extends from residues 61 to 152, and autoca-
talysis has broken the peptide bond between Gln152 and
Ser153. The catalytic domain extends from residues 153
to 447 but has two loops lacking electron density. The V
domain extends from residues 452 to 683 with two disor-
dered regions. While there is no electron density for the
polypeptide chain that connects the catalytic domain to
the V domain, the placement of the V domain in the overallts reserved
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The Crystal Structure of PCSK9model is certain for two reasons. First, with only four dis-
ordered residues in the linker between the catalytic and
V domains, the linker is not long enough to reach symme-
try-related V domains within the crystal lattice. Second,
Figure 1. Overall Structure of the PCSK9 Protein
Ribbons diagram of the structure with the prodomain in magenta, the
catalytic domain in wheat, and the V domain in blue. Thr61 marks the
first observed residue, and Gln152 marks the C terminus of the prodo-
main. Ser153 marks the N terminus of the catalytic domain.Structure 15, 54the assigned position of the V domain is consistent in both
of the crystal forms obtained with this protein. Although
the PCSK9 protein used for crystallization is glycosylated
at residue Asn533, there is very poor electron density for
the oligosaccharide and it was not included in the mod-
eled structure.
The PCSK9 Prodomain Inhibits Catalytic Activity
The core of PCSK9’s prodomain closely resembles the
prodomain of subtilisin (Gallagher et al., 1995; Jain et al.,
1998), with two a helices and a four-stranded antiparallel
b sheet. The b sheet forms the interface between the pro-
domain and the catalytic domain through an extensive
network of both hydrophobic and electrostatic interac-
tions, and in PCSK9 this interface buries 1300 A˚2 of sol-
vent-accessible surface from each molecule. The four C-
terminal amino acids of the prodomain (PCSK9 residues
149–152) bind at the catalytic site as a b strand that lies an-
tiparallel to a strand from the catalytic domain, in an anal-
ogous fashion to an inhibitory peptide (P4–P1, respec-
tively) (Figure 2A). Extending from the prodomain core
are 14 additional amino acids (Thr61–Leu74) ordered at
PCSK9’s N terminus (Figure 2B). This 14 amino acid ex-
tension begins with a b strand that packs parallel against
the core b sheet, extends into a 310 helix, and turns backFigure 2. The Prodomain Inhibitory Pep-
tide Binds in the Catalytic Site
(A) Stereo viewof the catalytic sitewith 2Fo Fc
electron density contoured at 1 s. P1 residue
Gln152 and P3 residue Phe150 are labeled.
His226 and Ser386 of the catalytic triad are
also shown.
(B) The N-terminal extension interacts with the
core b sheet and inhibitory peptide. The first
ordered residue in the subtilisin prodomain cor-
responds with PCSK9 amino acid residue
Pro75.5–552, May 2007 ª2007 Elsevier Ltd All rights reserved 547
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The Crystal Structure of PCSK9to reach the N terminus observed in the subtilisin prodo-
main. These additional N-terminal residues form extensive
contacts with the inhibitory peptide. The side chain of
Trp72 from the 310 helix makes a hydrophobic interaction
with the side chain of Phe150, the P3 residue. The side
chain of Arg73 forms hydrogen bonds with the side chain
of Glu145. Backbone hydrogen bonds are found between
the carbonyl of Trp72 and the amide nitrogen of Ser148,
and the amide nitrogen of Leu74 and the carbonyl of
Asp146.
The structure of thePCSK9prodomain/catalytic domain
complex exhibits a significant difference to the four previ-
ous subtilase complex structures. Crystals for all previous
complexes were grown using proteases with active-site
mutations that lessen or abolish their catalytic activity (Co-
mellas-Bigler et al., 2004; Gallagher et al., 1995; Jain et al.,
1998; Kim et al., 2004). In the case of subtilisin and kuma-
molisin, thesemutationswere required to prevent autocat-
alytic degradation of the prodomain and maturation of
the protease into its active form. In the case of fervidolysin,
inactive protease was required to obtain a homogenous
sample for crystallization. While fervidolysin and kumamo-
lisin also contain additional ordered amino acids at the
N termini of their prodomains, neither of these extensions
form extensive contacts with their prodomain C termini.
Inour structuralwork,wild-typePCSK9proteinwitha func-
tional catalytic triad was used. It is likely that the extra
stabilization of the inhibitory peptide in the catalytic site,
provided by the N-terminal extension of the prodomain,
blocks further access to the catalytic triad and prevents
a subsequent autocatalytic reaction from occurring.
PCSK9’s prodomain retains its structure and remains
tightly associated to the catalytic domain, where it inhibits
further catalytic activity.
In endeavors to obtain measurable catalytic activity,
multiple methods to facilitate the release of the prodomain
were investigated. Amino acid residues at the interface of
the pro- and catalytic domainsweremutated in an attempt
to weaken the interaction between these two domains.
Amino acid residues at the interface of the N-terminal ex-
tension and inhibitory peptide were mutated in an attempt
to weaken the stabilization of the inhibitory peptide in the
catalytic site and permit a second autocatalytic event.
Wild-type and correctly folded mutant proteins (as deter-
mined by secretion of nonaggregated protein) were ex-
posed to various buffer conditions (pH changes, high salt,
detergents, and denaturing reagents) in hopes of destabi-
lizing the complex. In all nondenaturing conditions tested,
the prodomain remained associated with the catalytic
domain. Under denaturing conditions dissociation was
observed, but the resulting catalytic domain formed high
molecular weight aggregates (unpublished data).
The Catalytic Domain
The architecture of PCSK9’s catalytic domain is similar to
that observed for other members in the subtilisin family.
The core of this domain is composed of a seven-stranded
parallel b sheet, flanked on both sides by a helices. The
N-terminal a helix of the catalytic domain has undergone548 Structure 15, 545–552, May 2007 ª2007 Elsevier Ltd All riga substantial shift in conformation, moving more than 25 A˚
from Gln152 (Figure 1), and is found in a position similar
to that observed with other mature subtilases (Gallagher
et al., 1995). It is possible that this conformational change,
brought about by autocatalysis, is the trigger required to
permit secretion. The loop that links the N-terminal helix
to the catalytic domain (residues 168–175) and a second
loop (residues 212–218) both lack electron density and
were notmodeled into the structure. Three disulfide bonds
are found within the catalytic domain. As previously seen
in related structures, two a helices from the catalytic do-
main form the interface for interaction with the prodomain.
The catalytic triad of PCSK9 is made up of residues
Asp186, His226, and Ser386. When compared to other
subtilases, minor differences can be seen in the positions
of the catalytic triad residues due to differences in the sur-
rounding amino acid residues (Betzel et al., 1988; Henrich
et al., 2003; Siezen and Leunissen, 1997). In PCSK9,
Pro288 causes a slight shift in the orientation of the side
chain of Asp186, and Ala390 causes a slight shift in the po-
sition of Ser386. Normally, the amino acid at the position
corresponding with Pro288 is a serine, whose free back-
bone amide nitrogen plays a role in the orientation of the
catalytic aspartic acid through a water-mediated hydro-
gen bond. The amino acid at the position corresponding
to Ala390 is normally a proline. The proline at this position
breaks an a helix and pushes the catalytic serine slightly
out toward solvent. In PCSK9 the a helix is able to con-
tinue, pulling the catalytic serine in toward the protein
where its side chain hydroxyl is 2.8 A˚ from the carbonyl
of Pro288. Although these differences are clearly not
enough to prevent PCSK9’s catalytic activity (as exempli-
fied by its autocatalysis in vitro), we find it interesting that
these normally highly conserved amino acids differ when
compared to other subtilases.
TheS1pocket of PCSK9 is shallowerwhen compared to
other subtilases. Based on sequence alignments (Siezen
and Leunissen, 1997), subtilisin-like serine proteases al-
most exclusively have glycine residues on both sides of
their S1 pockets. In PCSK9, one of these residues is an al-
anine rather than a glycine. The side chain of Ala290 pro-
trudes into the S1 pocket, thereby raising the floor of this
pocket. Gln152 from the prodomain binds at the S1 site
where its side chain curls up and out of the pocket and
forms hydrogen bonds to the backbone carbonyl of
Phe150 and the backbone amide nitrogen of Ala315.
The V Domain
The V domain of PCSK9 is a novel, cylindrically shaped
domain with quasi 3-fold internal symmetry (Figure 3 and
Figure S1). The principal fold for each of the three subdo-
mains within this domain is a b sandwich made up of six
antiparallel b strands in a truncated jelly-roll motif. Each b
sandwich is held together by three internal disulfide bonds
(from strands 1 to 6, 2 to 6, and 3 to 5), for a total of nine
disulfide bonds within the V domain. Other than the con-
served cysteine residues, there is low sequence identity
between the three subdomains. While there is clear overall
3-foldsymmetrywithin thisdomain, thesecondbsandwichhts reserved
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The Crystal Structure of PCSK9lacks electron density for strand 4 and has five rather than
six b strands. This strand is missing in the structures from
both crystal forms. The region of missing amino acid resi-
dues (572–584) contains three proline residues that possi-
bly prevent this segment from forming ab strand. In subdo-
mains 1 and 3, strand 4 packs against strand 5 from the
same subdomain and strand 3 from the neighboring sub-
domain. The lack of this strand leaves a cavity in the sur-
face of the V domain between subdomains 2 and 3, with
the space partially filled by a loop from subdomain 3.
While a structure similarity search utilizing the complete
Vdomain does not produce any goodmatches, SSM (Kris-
sinel and Henrick, 2004) returns a structurally related pro-
tein when a single b sandwich is used as the searchmodel.
Each single b sandwich of PCSK9 closely resembles the
N-acetylgalactosamine-binding lectin, Helix pomatia ag-
glutinin (HPA) (Sanchez et al., 2006). The b sandwich of
the HPA molecule is a six-stranded, truncated jelly roll
with one internal disulfide bond. In the HPAmolecule three
separate b sandwiches associate to form a homotrimer,
which then binds end-to-end with another homotrimer to
form the biologically active molecule. The V domain of
PCSK9 resembles the homotrimer of the HPA protein.
The interaction between the V domain and the catalytic
domain is not extensive, burying 700 A˚2 of solvent-
accessible surface from each molecule. There are three
direct hydrogen bonds at the interface of these domains.
The side chain of Asp480 from the V domain forms a hy-
drogen bond with the side chain of Thr407 from the cata-
lytic domain. The side chain of Gln413 from the catalytic
domain forms hydrogen bonds with the side chain of
Figure 3. The V Domain Has Quasi 3-Fold Internal Symmetry
Subdomain 1 is in blue, subdomain 2 is in green, and subdomain 3 is in
yellow. The b strands in subdomain 1 are numbered. Subdomain 2 is
missing b strand 4 (disordered region between Leu571 and Pro585)
that would fill the space between subdomains 2 and 3. The N-
(Gly452) and C termini (His683) of the V domain are shown.Structure 15,Glu481 and the backbone carbonyl of Cys526. The re-
maining direct interactions between these domains are
hydrophobic and van der Waals in nature. The interaction
surfaces of these two domains are not complementary,
with more than 15 ordered water molecules in the cavity
between them. Although the interaction between the V do-
main and the catalytic domain is comparable in both of the
crystal forms obtained, it is conceivable that this domain/
domain conformation is a low-energy conformation uti-
lized during crystal packing and is not representative of the
protein in solution, or that adopted when performing its
physiological function.
Examination of the V domain reveals an overall large
number of histidine residues, the majority of which cluster
on a surface proximal to the groove between subdomains
2 and 3 (Figure 4). With a pKa of 6, histidine residues
have been shown to act as switches in pH-dependent pro-
tein-protein interactions (Doi et al., 1994; Rudenko et al.,
2002). Using Biacore analysis, we have found that wild-
type PCSK9 interacts more tightly with the LDLR at pH
5.2 (KD = 35 nM) when compared to pH 7.4 (KD = 840
nM) (Figure S2). Unlike the LDL/LDLR interaction, which
dissociates at endosomal pH (5–6) (Brown and Goldstein,
1986), the PCSK9/LDLR interaction is stronger at endoso-
mal pH.
Conclusions
Many PCSK9 gain-of-function and loss-of-function muta-
tions have been previously described in the literature
Figure 4. The V Domain Histidine Patch
The cluster of histidine amino acid residues on the V domain maymed-
itate a pH-dependant protein-protein interaction. Twelve of the 14 his-
tidines in the V domain are visible in the figure. The subdomains are
colored as in Figure 3.545–552, May 2007 ª2007 Elsevier Ltd All rights reserved 549
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2006), and the structure of PCSK9 helps to elucidate how
some of these mutations impart their effect. Loss-of-func-
tion mutations DArg97 and Gly106Arg are found in the
prodomain of PCSK9 and result in a protein that is defec-
tive in autocatalysis and is not secreted from the cell.
Arg97 is found within an a helix in the prodomain, and re-
moval of the amino acid from this secondary structure el-
ement would disrupt its fold and likely prevent the correct
folding of the entire prodomain. The Gly106Arg mutation
occurs in a loop between an a helix and b strand, and it
is likely that the flexibility allowed by a glycine amino
acid residue at this position is required for correct folding
of the prodomain. The Leu253Phe loss-of-function mutant
also effects the autocatalysis of PCSK9. Residue Leu253
is found between the S2 and S4 pockets of the catalytic
site, and it is likely that a larger phenylalanine at this posi-
tion disrupts the binding of the peptide required for auto-
catalysis. The Cys679X loss-of-function mutation causes
a 14 amino acid truncation at the C terminus of the protein
and results in a protein that is retained in the endoplasmic
reticulum. Cys679 from b strand 6 forms a disulfide bond
with Cys608 from b strand 1 in subdomain 3 of the V do-
main. Loss of the disulfide bond between strands 1 and
6 likely prevents the V domain from folding correctly,
which in turn prevents its secretion from the cell.
The specific interactions between PCSK9 and the LDLR
remain to be elucidated, and it is likely that knowledge of
this interaction will be beneficial in completing the picture
of how PCSK9 regulates extracellular levels of the LDLR.
However, the structure of PCSK9 does shed much light
on its biochemical characteristics and biological function.
While the autocatalytic activity of PCSK9 has been shown
to be required for the PCSK9 protein to be secreted from
cells, the stabilization of the inhibitory peptide in the cata-
lytic site and the tight association of the prodomain to the
catalytic domain explain why robust measurements of
PCSK9 catalytic activity have not been obtained. Although
the structure does not rule out the activation of PCSK9
catalytic activity by additional proteases or under certain
conditions, such as the binding of an additional regulatory
protein or through displacement of the prodomain by a
unique substrate protein, the results seen here agree
with the current hypothesis on how PCSK9 lowers LDLR
levels (Horton et al., 2007). In this model, PCSK9 autoca-
talysis triggers its progression through the secretory path-
way, and it interacts directly with the LDLR either within
this pathway or on the cell surface. The PCSK9/LDLR
complex subsequently enters the endosomal pathway.
The ability of PCSK9 to interact with the LDLR at endoso-
mal pH prevents the recycling of the LDLR, and the
PCSK9/LDLR complex shuttles to the lysozome, where
degradation of the LDLR occurs. While we postulate that
the histidine-rich patch proximal to the groove on the V
domain may be important for mediating the PCSK9/
LDLR interaction, confirmationmust await a detailedmap-
ping of surface residue mutations that result in attenuated
receptor-binding affinity. A therapeutic that inhibits the ac-
tivity of PCSK9 anywhere along this pathway could poten-550 Structure 15, 545–552, May 2007 ª2007 Elsevier Ltd All rigtially benefit patients suffering from hypercholesterolemia
by decreasing their levels of plasma LDL-cholesterol.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization of PCSK9
Human PCSK9 (residues 31–692) was cloned into a pFastBac vector
(Invitrogen) with an N-terminal His6 affinity tag and TEV protease cleav-
age site. The honeybee melittin signal peptide was added by PCR.
Recombinant baculovirus was prepared with the Bac-to-Bac system
(Invitrogen). Trichoplusia ni cells (High Five, Invitrogen) at 1 3 106
cells/ml were infected at a multiplicity of infection (MOI) of 0.01 with re-
combinant baculovirus. Each liter of culture media was supplemented
with 5 ml of Antibiotic-Antimycotic Solution (MediaTech) and 5 mM
E-64 protease inhibitor (Sigma). Conditioned media was harvested af-
ter 72 hr and filtered through a 0.45 mm filter. The cleared supernatant
was concentrated from 10 to 0.6 liters with a Prep/Scale TFF 6.0 ft2
10 kD cartridge according to the manufacturer’s instructions (Milli-
pore). The concentrator retentate was bound to His-Select Nickel
Affinity Gel beads (Sigma) and eluted with an imidazole gradient. The
PCSK9-enriched sample was further purified by ion-exchange chro-
matography using a Mono Q 10/100 column (GE Healthcare) with elu-
tion by a NaCl gradient. The melittin-His6 tag was then removed by
overnight cleavage with rTEV at 4C. Following cleavage, PCSK9
was purified by size-exclusion chromatography with a Superdex 75
column (GE Healthcare). The final step of the purification again utilized
a Mono Q 10/100 column, this time eluting with a pH gradient. Purified
PCSK9 was buffer-exchanged into 10 mM Tris (pH 7.5) and 50 mM
NaCl and concentrated to 6.5 mg/ml for crystallization. Crystals were
grown using the vapor diffusion method by mixing equal volumes of
protein and well solution. PCSK9 crystallized in two crystal forms,
and in both cases microseeding was used to optimize crystal growth.
Crystal form 1 grew from a well solution of 0.1 M NaOAc (pH 4.6), 10%
glycerol, and 4.1MNH4OAc. Crystal form 2 grew from awell solution of
0.1 M Tris (pH 7.8), 0.2 M (NH4)2SO4, and 13% PEG 3350. For both
crystal forms, crystals were cryoprotected by supplementing the
mother liquor with glycerol and were flash cooled in liquid nitrogen
prior to data collection.
Data Collection and Structure Determination
Diffraction data were collected at 90K at the Berkeley Advanced Light
Source beamline 5.0.2, and processed using Denzo and Scalepack
(Otwinowski et al., 2003). Crystal form 1 grew in the space group
P213 and was used to generate heavy-atom derivatives. Native crys-
tals were derivatized with mercury by soaking overnight in 10 mM eth-
ylmercuryphosphate. For the xenon derivative, native crystals were
exposed to xenon gas at 200 psi for 10 min. SOLVE (Terwilliger and
Berendzen, 1999) was used to determine the position of one mercury
and two xenon atoms by MIRAS. CNX (Brunger et al., 1998) was used
to refine the sites and calculate phases. Density modification was used
to improve and extend phases to 3.1 A˚, and maps were calculated.
Protein secondary structure was easily interpretable in the experimen-
tal electron density maps. Multiple rounds of manual model building
were performed with Quanta (Accelrys), followed by positional and
grouped B factor refinement with CNX. Crystal form 2 grew in the
space group P212121 and diffracted to significantly higher resolution.
The partial PCSK9 model from crystal form 1 was used as a search
model in MOLREP from the CCP4 program suite (CCP4, 1994) to
find a molecular replacement solution for crystal form 2. Further model
building and refinement were continued against the 2.3 A˚ data set from
crystal form 2. Structure improvement proceeded with multiple rounds
of manual model building in Quanta, followed by positional and individ-
ual B factor refinement using CNX. Simulated annealing omit maps
were calculated to confirm the PCSK9 model. Accessible surface
area was calculated with AREAINMOL in CCP4. Analysis with the pro-
gramPROCHECK in CCP4 shows that themodel has 90.4%of the res-
idues in the most favored region of the Ramachandran plot, with anhts reserved
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The Crystal Structure of PCSK9additional 9.4% in allowed regions. Asp651 is in a disallowed region,
but the electron density confirms its orientation in the model. The final
model has an R of 19.6% and an Rfree of 23.2%, and it includes 87.2%
of the PCSK9 amino acid residues, 215 water molecules, and 2 sulfate
ions. Figures were made using PyMOL (DeLano, 2002).
LDLR/PCSK9 Binding Assay
Surface plasmon resonance experiments were performed using a Bia-
core 2000 (GE Healthcare). LDLR (R&D Systems) was immobilized to
a research grade CM5 sensor chip by amine-coupling at levels that
gave a maximum analyte binding response (Rmax) of no more than
150 RU. Binding affinities of wild-type human PCSK9 to LDLR were
measured at pH 7.4 (HPS-P buffer supplemented with 0.01% BSA
and 2 mM CaCl2) and acidic pH 5.2 (Tris-succinate buffer supple-
mented with 0.01% BSA and 2 mM CaCl2). For the pH 5.2 binding
affinity measurement, the LDLR was equilibrated with pH 5.2 buffer
before the PCSK9 was flown over the immobilized LDLR.
Supplemental Data
Supplemental Data include two figures and are available at http://
www.structure.org/cgi/content/full/15/5/545/DC1/.
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